Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (May 2021)
48 slides from Genprex's investor presentation, May 13, 2021
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex’ REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX May 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements contained inthis presentation regarding matters that are not historical facts are forward-looking statements" within the meaning ofthe Private Secures Ligation Reform Act of 1995, Because such statements are subject to risks and uncertainties, actual results may
Slide 3: GNPX at a Glance
GNPX AT A GLANCE company | symBo. | ExcHANcE | sHAREPRICE| MaRKercap | 1°DAY AVG oneal VOLUME | OUTSTANDING Genprex, Inc. GNPX Nasdaq $3.36 159M, 763k 47,363,729 All data is as of May 10, 2021, except for cash, which is as of March 31, 2021. Genprex assagenex 3
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Novel gene therapies addressing cancer and diabetes [Addressing unmet medical need in large markets through the bulldout ofa robust pipeline of new drug candidates and drug combinations Leveraging a gene therapy platform: Genprex's non-viral Oncoprex® nanoparticle delivery syst
Slide 5: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM FIRST SYSTEMIC GENE THERAPY USED FOR CANCER IN HUMANS LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP. SELLING CANCER DRUGS FDA FAST TRACK DESIGNATION ed DEMONSTRATED CLINICAL ACHIEVEMENT INITIATING TWO LUNG CANCER TRIALS
Slide 6: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE biscovery CCINICAL ‘CLINICAL, CUNICAL eemeeets| (BieHAse PHASE? PHASE 3 ‘ONCOLOGY Acelaimn1 Acclaim -2 z= ==> —_a ——IE ‘onc-ooz ‘VARIOUS ONCOLOGY TARGETS DIABETES — “Fr US FDA Fst Tak Deigraton © Genprex Nasdag:onex 6
Slide 7: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES * Genprex’s oncology combination treatment Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes, immunotherapies. ‘© May reduce or eliminate daily b
Slide 8: Oncology Program
Slide 9: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS MOST COMMON LUNG CANCER TAGRISSO 2020 SALES NSCLC represents the majority of all lung cancers. AstraZeneca's highest grossing product. WORLDWIDE CASES. KEYTRUDA 2020 SALES More than two million cases per year worldwide. Merck's highest grossing product. 2
Slide 10: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM. The first systemic gene therapy delivery platform for cancer GENES Multiple tumor suppressor genes SYNERGIES ‘Advanced approach using combination therapy CANCERS Multiple cancers Nasdaq: GNPX 10
Slide 11: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS: Positively charged TUSC2 gene nanoparticle [Cassette S) 2° Negatively charged cancer cell Nanoparticle attaches Cancer killing genes Cell death to cancer cell integrate into cell Our non-viral, biodegradable, p
Slide 12: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells, Elevated glycolysis in cancer cells lead to a higher secretion of, lactate Secreted lactate ions rem
Slide 13: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 x CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS + MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdag: GNPX 13,
Slide 14: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY, THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Cell Survival Proliferation Nasdag: GNPX 14
Slide 15: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM immunomodulation of Carbo + Pembro + TUSC2 demonstrates rationale for the Acclaim-1 and Acclaim-2 clinical trials, treating patients who show progression after treatment with Tagrisso or Keytruda. Note: Treg and Myeloid cells are limmunesuppressve A. Aetive Tcetls
Slide 16: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n: Maximum Tolerated
Slide 17: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE PRIOR THERAPY HUME ie THERAPY Positive (exon 18420) Complete Response Chemo 3 Negative 24% regression Target Lesion Chemo / anti-PD1 2 30% regression one Target Lesion Negat
Slide 18: REQORSA + Tarceva Combination: Swimmer Plot
EGFR status/mutation REQORSA + TARCEVA COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative 4 Negative 4 Positive (exon 18+20) + Negative 4 Negative 4 Negative 4 Negative 4 Negative 4 Positive (exon 21) 4 Negative 4 Negative 4 Positive (exon 21) 4 sD ‘# Chemotherapy ‘4 Chemotherap
Slide 19: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth in Tagrisso-Resistant Tumors
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN TAGRISSO-RESISTANT TUMORS ’ sai ee sentntne vo k + — Osimertiib+TUSC2 combination on . THio76-08iR tumors in NG mice Dab crine TSC coca ma i" F wo Evo E 5 & ‘9 100- 2 3 ba 5 0 manmons — B 2 2 =e eS = ° ° DE 025 029 052 O36 De Ds Dat 025 029 032 036
Slide 20: Acclaim-1 General Study Characteristics
Aedlaimn> GENERAL STUDY CHARACTERISTICS + REQORSA in combination with AstraZeneca's Tagrisso for NSCLC + Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso + 15 US. sites + ~92 patients Phase 1: 9-18 patients Phase 2:74 patients + Interim analysis at 51 events (ie, dise
Slide 21: Acclaim-1 Study Design and Endpoints
i] stylys Acclaim -1 5 fora dlnse extaltiontar PRIMARY ENDPOINT w Zz REQORSA in combination with pe ose. mite Sxl ciy YS Tagrisso zz PRIMARY ENDPOINT SECONDARY ENDPOINTS : ei + Progression free survival (PES) + Overall response rate + Randomized 1 open-label," pelimprovement of REQORSA combination |
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model 2 oo. g Days TUSC2+anti-PD1 exhibit greater antitumor activity than US a eo ucombinanonserr icantly prolonged either agent alone or control. sur
Slide 23: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda ‘Strong antitumor immune responses of anti-PD1 were found against PDX tumors developed in humanized mice. nn a ann 2 REQORSA + Keytruda + Chemo REQORSA+anti-PD
Slide 24: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo + REQORSA enhances the efficacy of chemo-Immunotherapy on KL-mutant lung metastases in humanized mice. + Triple combination demonstrated strong antitumo
Slide 25: Acclaim-2
ost {TTS Acclaim -2 GENERAL STUDY CHARACTERISTICS + Phase 1/2 study of REQORSA in combination with Merck & Co's Keytruda for NSCLC + Late-stage NSCLC patients whose disease progressed after responding to Keytruda ACCLAIM-2 RATIONALE + Keytruda mo! ve than Keytruda alone in increasing the sun humaniz
Slide 26: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET ighted by important process improvements proved economies of scale. + Successful completion of technology transfer and scale-up of REQORSA + GMP production provides supply for two upcomi
Slide 27: Diabetes Program
ns Ww cs oY <9 of
Slide 28: Diabetic Patients in Need of Advanced Therapy
DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS. Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S', or 10 percent of the US. population. May replace daily burden of blood glucose ‘monitoring and insulin replacement
Slide 29: GPX-002 Replenishes Levels of Insulin
GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an tomed ‘AAY vector to deliver the Pdx! and MafA genes to verona iy the pancreas. rar inision ‘Transforms alpha cells in the pancreas into stacy functional beta-like cells, which
Slide 30: Key Milestones Through 2021 & Beyond
KEY MILESTONES THROUGH 2021 & BEYOND COMPLETED Successful completion of technology transfer and scale-up of REQORSA, Initiated site recruitment for both Acclaim clinical trials Reported preclinical data for REQORSA in combination with targeted therapies and immunotherapies Received Centralized IRB A
Slide 31: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS lovance Blotherapeutice Mirat'Therapeutcs MRT ‘syndax Phacmaceuticals SNOX Turing Point Therapeutics Ten Genprex, Ine. onex Nasdaq Nasdaq Nasdaq ‘Melanoma, Head and Neck, Cerval, NSCLC, Chronic Lymphocytic Leukemia NSCLC, Colorectal, Renal ell Ovarian Solid T
Slide 32: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman, President & Chief Executive Officer 30+ years of expertise in corporate law, including Corporate governance, in biotech industry + Former owner of securities broker dealer fiem MICHAEL REDMAN Executive VP & Chief Operating Officer + 30+ ye
Slide 33: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD Senior Vice President, Intellectual Property and Licensing + 20+ years of expertise in biotech IP law, business ‘development, licensing transactions + Seasoned IP executive and attorney SHANNON INMAN Vice President of Global Clinical Operations +
Slide 34: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD. FACS, Chairman Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracic and Cardiovascular Surgery; Chief, Section of Thoracic Molecular Oncology; Professor of Molecular and Cellular Oncology; UT MD Anderson Cancer Center
Slide 35: Meet Our Team: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD MICHAEL MORSE BR peas MD, MHS, FACP » , + Professor of Meine, Dison of Medical Oncology + Chief Executive Officer of Cancer Insight LLG 3 ike Oeertent of apap Dene unveny ei SGC aR ERC + Research expertise in targeted therapes and + Professor of Surgery at Unifo
Slide 36: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS. ( » RODNEY VARNER, JD Ch f the Board airman of the Boar WN BRENT LONGNECKER Board Director + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm Chief Executive Officer, Longnec
Slide 37: 21st Century Gene Therapies
21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP: TRANSFORMATIONAL SELLING DRUGS FAST TRACK DESIGNATION PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS:
Slide 38: Genprex Contact
oO Genprex’ NASDAQ: GNPX (877) 774-GNPX | investors@genprex.com Nasdag: GNPX
Slide 39: Appendix
Slide 40: Preparing to Initiate Two New Combination Clinical Trials
PREPARING TO INITIATE TWO NEW COMBINATION CLINICAL TRIALS = o—= Ss KEYTRUDA {hy gaa — {4 (pembrolizumab) «rjcsn:om He Teatisso™ ons omy ‘ONCOPREX® Nanoparticle Delivery System Is the lipid nanoparticle delvery system used in REQORSA™. Nasdag: GNPX
Slide 41: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES ‘The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against which no targeted agents have been developed. + Regulation of Malignant Tumor Growth + insensitivity to Growth-inhibitory Signals + Evasions of Progr
Slide 42: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells No need to attac
Slide 43: Why TUSC2?
WHY TUSC2? + 80% of all lung cancer cells lack the TUSC2 tumor suppressor gene + Loss or reduction of TUSC2 expression is associated with significantly worse overall survival + Premalignant lesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia © Genprex Nasdag:
Slide 44: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS ‘The most common viral vectors are adenoviruses and retroviruses + High level of transfection efficiency + Generally stable + Less specificity of target cells + Can be immunogenic because capsid and viral proteins cause inflammation + Reported cases of death and causing l
Slide 45: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: Thyroid Renal Breast Head & Neck Mesothelioma Ovary 9 and invasion of ovarian cancer ell by inhibiting ch 5 sasdaa: GNPX
Slide 46: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE eae (Osimertinib+TUSC2 on AS4S lung met in NSG mice PAN. Los re ‘Week 3 Figure 4A, TUSC2 combination with Osimertinid inhibits tumor growth and significantly prolongs survival. A) top t
Slide 47: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Carbo+Pembro Effect of Carbo+Pembro+TUSC2 on Tusc2Carbo+Pembro_+TUSC2 ‘A549 lung met on Hu-NSG % of change (wk2 vs wk5) tumor intensity Pembrolizumab is the generic name for Keytruda, Nasdag: GNPX 47
Slide 48: Effect of REQORSA + Carbo + Keytruda on Humanized Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on A549 lung met on Hu-NSG 61099 No treatment “= Tusc2 op A109) Carbo+Pembro z —~ CatborPembrosTUSC2 & 2x10° 3 4 = 2x108 B.sx108 4x108 et a 5x107 J : 0 i4 D28 D35 ** p= 0.0003 vs No treatment 0.